Cargando…

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

Different highly effective interferon-free treatment options for chronic hepatitis C virus (HCV) infection are currently available. Pre-existence of resistance associated variants (RAVs) to direct antiviral agents (DAAs) reduces sustained virologic response (SVR) rates by 3–53% in hepatitis C virus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietz, Julia, Susser, Simone, Berkowski, Caterina, Perner, Dany, Zeuzem, Stefan, Sarrazin, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552686/ https://www.ncbi.nlm.nih.gov/pubmed/26317755 http://dx.doi.org/10.1371/journal.pone.0134395

Ejemplares similares

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy
por: Dietz, Julia, et al.
Publicado: (2016)

Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C
por: Susser, Simone, et al.
Publicado: (2014)

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
por: Mücke, Marcus M., et al.
Publicado: (2019)

A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers
por: Vermehren, Johannes, et al.
Publicado: (2012)

Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity
por: Welker, Martin-Walter, et al.
Publicado: (2012)

Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients
por: Grammatikos, Georgios, et al.
Publicado: (2014)

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
por: Welsch, Christoph, et al.
Publicado: (2008)

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
por: Mölleken, Christian, et al.
Publicado: (2019)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
por: Graf, Christiana, et al.
Publicado: (2020)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage
por: Hostager, Reilly, et al.
Publicado: (2019)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis
por: Dultz, Georg, et al.
Publicado: (2013)

Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
por: Yelemkoure, Edwige T., et al.
Publicado: (2021)

Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals
por: Sparvoli, Jucéli Márcia Hendges, et al.
Publicado: (2023)

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
por: Chaturvedi, Nimisha, et al.
Publicado: (2019)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
por: Howe, Anita Y.M., et al.
Publicado: (2022)

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
por: Adiwijaya, Bambang S., et al.
Publicado: (2010)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
por: Wiegand, Steffen B., et al.
Publicado: (2015)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms
por: Vermehren, Johannes, et al.
Publicado: (2017)

Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma
por: Bihrer, Verena, et al.
Publicado: (2011)

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
por: Polilli, Ennio, et al.
Publicado: (2016)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
por: Sahin, Ahmet, et al.
Publicado: (2023)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
por: Dietz, Christopher, et al.
Publicado: (2022)

Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review
por: Rana, Ramesh, et al.
Publicado: (2021)

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
por: Adiwijaya, Bambang S., et al.
Publicado: (2012)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla, Maheeba, et al.
Publicado: (2019)

Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents
por: Hsu, Yao-Chun, et al.
Publicado: (2022)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rem2808m6p1p3tv9r42mlvnm46